- Introduction to Clinical Research Training
- Medical Education
- United Kingdom Clinical Scholars Research Training
- Vanderbilt Hall
- Financial Aid
- Office of the Registrar
- Campus Planning and Facilities
- Ombuds Office
- Committee on Microbiological Safety
- Human Resources
- HMS Foundation Funds
- Office for Academic and Clinical Affairs
- Joint Committee on the Status of Women
- The Academy
- Global Health Research Core
- Global Clinical Scholars Research Training Program
- HMA Standing Committee on Animals
- Office of Research Compliance
- Global & Community Health
- Harvard Medical School Event Calendar
- Contact @HMS
- Office of Diversity RIA Program
- The Dean's Perspective
- Department of Pathology
- Harvard Mahoney Neuroscience Institute
- OHRA Home
- Office of Research Subject Protection
- Tools and Technology
- Alumni Association
- HMS Community Values Initiative
- HMS Information Technology
- HMS TransMed Program
- Introduction to the Practice of American Medicine
- Office of Communications & External Relations
- Office of Global Education
- Shenzhen-HMS Initiative in International Education
- South American Clinical Research Training
- test page
- Safety Quality and Informatics Leadership
- Human Resources
- Jobs @ HMS
- Contact us
- Dental Medicine
- Harvard University
Move It and Lose It
June 5, 2014
A natural hormone that is increased by physical exercise and by exposure to cold improves blood-sugar control, suppresses inflammation and burns fat to mold leaner bodies in mice, report scientists at Harvard Medical School and Dana-Farber Cancer Institute.
The hormone, called meteorin-like or Metrnl, can be made in the laboratory. Its health-promoting properties make it a promising candidate for treating obesity and other metabolic diseases, inflammation, and possibly other disorders, said principal investigator Bruce Spiegelman, the Stanley J. Korsmeyer Professor of Cell Biology and Medicine at HMS and Dana-Farber.
“This might have interesting therapeutic potential for several diseases,” said Spiegelman. “Because it targets the immune cells involved in tissue repair it will also be interesting to see if this protein affects muscle repair in certain neuromuscular diseases.”
Reporting in Cell, the researchers said that extra Metrnl injected into mice achieved some of the same effects as exercise. It decreased their body fat by 25 percent and caused them to lose weight even on a high-fat diet. It improved their blood sugar control, stimulated conversion of chemical energy to heat, and turned on anti-inflammatory genes.
The meteorin-like protein had previously been identified, but the new study is the first to reveal its role as a hormone—a biological messenger in blood—involved in metabolism and energy balance, according to the researchers. The study adds Metrnl to an emerging picture of why exercise has many healthful benefits, from weight loss to suppressing inflammation to combating metabolic diseases.
In addition, Metrnl has an important role in dialing up fat-burning to maintain core heat production in mice exposed to cold temperatures, the study revealed. The researchers said this indicates that Metrnl is part of the body’s mechanism for adapting to environmental changes.
Unlike other exercise-related proteins that stimulate thermogenesis—burning calories to create heat—Metrnl works mainly through the immune system rather than directly on fat cells, said Spiegelman. The scientists found that Metrnl activates an alternative molecular pathway by which immune cells are recruited to enter fatty tissue, where they trigger the fat-burning process.
“The idea of a protein acting primarily through the immune cells in the fat is pretty amazing, at least in our view,” Spiegelman said.
The Metrnl findings come two years after the Spiegelman group isolated a different protein, irisin, produced in muscles by endurance as opposed to resistance exercise, which stimulates Metrnl secretion. Irisin also promotes the browning of fat to release energy and caused mice to lose weight. Like Metrnl, irisin improves glucose tolerance, which helps prevent diabetes.
From the viewpoint of developing therapies, “it is a good thing to have molecules that work through different pathways,” said Spiegelman. Irisin is being studied as a potential treatment for obesity and type 2 diabetes and has been licensed commercially.
The research was funded by grant DKO61562 from the National Institutes of Health.
Adapted from a Dana-Farber news release.